DocDollars

Noven Pharmaceuticals, Inc.

FL · United States · Reporting entity ID 100000000219

Total reported 2019–2025
$16.2M
#365 of 2,960 reporting companies — 0% of all reported industry payments
$817K in general payments across 1,405 records, plus $15.4M in research funding across 1,014 records.

How it breaks down

General payments $817,213
Research funding $15,432,465

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Noven Pharmaceuticals, Inc. reported $16.2M to US doctors and teaching hospitals from 2019 to 2025, ranking #365 of 2,960 reporting companies. 95% of that was research funding and 5% general payments such as consulting, speaking, food and travel. 1,405 general payment records and 1,014 research records were filed.

Common questions about Noven Pharmaceuticals, Inc.

How much has Noven Pharmaceuticals, Inc. paid US doctors?

Noven Pharmaceuticals, Inc. reported $16,249,678 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $817,213 in general payments, $15,432,465 in research funding.

How does Noven Pharmaceuticals, Inc. rank among drug and device companies?

It ranks #365 of 2,960 reporting entities by total reported value, about 0% of all industry payments in the dataset.

Does a payment from Noven Pharmaceuticals, Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.